title: Exercise Intervention in Pediatric Patients with Solid Tumors: The Physical Activity in Pediatric Cancer Trial.
abstract: The randomized controlled trial "Physical Activity in Pediatric Cancer" determined the effects of an inhospital exercise intervention combining aerobic and muscle strength training on pediatric cancer patients with solid tumors undergoing neoadjuvant chemotherapy.
  
  
  
  Participants were allocated to an exercise (n = 24, 17 boys; mean ± SEM age, 10 ± 1 yr) or control group (n = 25, 18 boys; 11 ± 1 yr). Training included three sessions per week for 19 ± 2 wk. Participants were assessed at treatment initiation, termination, and 2 months after end treatment. The primary endpoint was muscle strength (as assessed by upper and lower-body five-repetition-maximum tests). Secondary endpoints included cardiorespiratory fitness, functional capacity during daily life activities, physical activity, body mass and body mass index, and quality of life.
  
  
  
  Most sessions were performed in the hospital's gymnasium. Adherence to the program averaged 68% ± 4% and no major adverse events or health issues were noted. A significant interaction (group-time) effect was found for all five-repetition maximum tests (leg/bench press and lateral row; all P < 0.001). Performance significantly increased after training (leg press: 40% [95% confidence interval [CI], 15-41 kg); bench press: 24% [95% CI, 6-14 kg]; lateral row 25% [95% CI, 6-15 kg]), whereas an opposite trend was found in controls. Two-month post values tended to be higher than baseline for leg (P = 0.017) and bench press (P = 0.014). In contrast, no significant interaction effect was found for any of the secondary endpoints.
  
  
  
  An inhospital exercise program for pediatric cancer patients with solid tumors undergoing neoadjuvant treatment increases muscle strength despite the aggressiveness of such therapy.
authors.affiliation: 1Research Institute of the Hospital '12 de Octubre' (i + 12), Madrid, SPAIN; 2Spanish Network for Biomedical Research in Rare Diseases (CIBERER), U723, SPAIN; 3School of Doctorate Studies and Research, European University, Madrid, SPAIN; 4Research Centre in Physical Activity, Health and Leisure, Faculty of Sport, University of Porto, PORTUGAL; 5Innate Immune Research Group, IdiPAZ, Madrid, SPAIN; 6Department of Health Sciences, GIDFYS, European University Miguel de Cervantes, Valladolid, SPAIN; 7Department of Hematology-Oncology and Stem Cell Transplantation, Children's Hospital Niño Jesús, Madrid, SPAIN; 8Andrews Research and Education Foundation, Gulf Breeze, FL; and 9Department of Pediatric Hemato-Oncology and Stem Cell Transplantation, University Hospital La Paz, Madrid, SPAIN.
authors.forename: Carmen
authors.initials: C
authors.lastname: Fiuza-Luces
authors.forename: Julio R
authors.initials: JR
authors.lastname: Padilla
authors.forename: Luisa
authors.initials: L
authors.lastname: Soares-Miranda
authors.forename: Elena
authors.initials: E
authors.lastname: Santana-Sosa
authors.forename: Jaime V
authors.initials: JV
authors.lastname: Quiroga
authors.forename: Alejandro
authors.initials: A
authors.lastname: Santos-Lozano
authors.forename: Helios
authors.initials: H
authors.lastname: Pareja-Galeano
authors.forename: Fabián
authors.initials: F
authors.lastname: Sanchis-Gomar
authors.forename: Rosalía
authors.initials: R
authors.lastname: Lorenzo-González
authors.forename: Zoraida
authors.initials: Z
authors.lastname: Verde
authors.forename: Luis M
authors.initials: LM
authors.lastname: López-Mojares
authors.forename: Alvaro
authors.initials: A
authors.lastname: Lassaletta
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Fleck
authors.forename: Margarita
authors.initials: M
authors.lastname: Pérez
authors.forename: Antonio
authors.initials: A
authors.lastname: Pérez-Martínez
authors.forename: Alejandro
authors.initials: A
authors.lastname: Lucia
mesh_terms: D061725:Accelerometry; D000203:Activities of Daily Living; D015992:Body Mass Index; D000072599:Cardiorespiratory Fitness; D002648:Child; D005081:Exercise Therapy / Q000009:adverse effects / Q000379:methods*; D017079:Exercise Tolerance; D005260:Female; D006801:Humans; D008297:Male; D053580:Muscle Strength; D020360:Neoadjuvant Therapy; D009369:Neoplasms / Q000628:therapy*; D010349:Patient Compliance; D011788:Quality of Life; D055070:Resistance Training / Q000009:adverse effects